Revvity Signals Banner Ad (Nov-Dec)

EDITORIAL SECTION

KNOWLEDGE BANK

  • Techno Trends

    Lilly’s Jaypirca Gains FDA Approval for First-Line CLL/SLL Treatment

    Eli Lilly and Company has received approval from the US Food and Drug Administration FDA for an additional indication for Jaypirca pirtobrutinib in adults with previously untreated chronic lymphocytic leukaemia CLL or small lymphocytic lymphoma SLL without a known p deletion The approval enables Jaypirca to be used as a firstline treatment

TOP ARTICLES

  • 3

    When Legacy Systems Hold Back Innovation

    Lakshmi

    Aging technology quietly taxes every ambition a pharmaceutical enterprise holds — slowing drug development, fracturing data, and turning each new initiative into a negotiation with the past. Yet...

press releasesRead more...

Shionogi Completes Acquisition of IntraBio Inc. and Adds AQNEURSA® (levacetylleucine) to Growing Rare Disease Global Portfolio

Shionogi Co Ltd Head Office Osaka Japan Chief Executive Officer Isao Teshirogi PhD hereafter Shionogi announced that it has completed the acquisition of IntraBio Inc IntraBio The acquisition adds AQNEURSA levacetylleucine and additional rare disease capabilities to Shionogis growing global portfoli...

Nelkarmi (neladalkib) approved in the US for previously-treated advanced ALK-positive non-small cell lung cancer

GSK plc LSENYSE GSK today announced the US Food and Drug Administration FDA has granted accelerated approval to Nelkarmi neladalkib for the treatment of adults with locally advanced or metastatic anaplastic lymphoma kinase

Stipple Bio Announces Multi-Target Multi-Modality Oncology Research Collaboration with Lilly

Stipple Bio Inc a private biotechnology company harnessing epitopelevel precision to create targeted cancer therapies today announced that it has entered into a multitarget multimodality strategic research collaboration and license agreement with Eli Lilly and Company

Cardiff Oncology Receives FDA Fast Track Designation for Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer

Cardiff Oncology Inc Nasdaq CRDF a clinicalstage biotechnology company targeting RASmutated cancer by leveraging PLK inhibition today announced that the US Food and Drug Administration FDA has granted Fast Track designation to onvansertib in combination

24 - 27

Nov 2026

Pharmtech & Ingredients 2026

Crocus Expo, Pavilion 2, Mosco...

24 - 25

Nov 2026

BioPharma Deals Conference 2026

Science Congress Center, Munic...

26 - 28

Nov 2026

One Health Conference 2026

Thapar Institute of Engineerin...

01 - 03

Dec 2026

Pharmaceutical Launch Excellence Summit

Novotel Amsterdam City, Nether...

01 - 03

Dec 2026

10th Antifibrotic Drug Development

Boston, MA at the Hotel Common...

02 - 04

Dec 2026

Genome Informatics 2026

Wellcome Genome Campus, UK

03 - 04

Dec 2026

03 - 04

Dec 2026

LATEST NEWSRead more...

Erasca Partners with Bristol Myers Squibb to Evaluate ERAS-0015 Combination Therapy for Pancreatic Cancer

Clinicalstage precision oncology company Erasca has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb BMS to evaluate its investigational drug ERAS in combination with navlimetostat BMS an investigational PRMT inhibitor developed by BMS

GATC Health and Hesperos Join Forces to Develop AI and Human-on-a-Chip Workflow for Preclinical Testing

GATC Health Corp and Hesperos Inc have entered into a strategic collaboration to develop an integrated New Approach Methodologies NAMs workflow aimed at reducing the time and cost of preclinical drug testing before human clinical trials

Novartis’ Cosentyx becomes first anti-IL-17 biologic approved for polymyalgia rheumatica

Novartis has received approval from the US Food and Drug Administration FDA for Cosentyx secukinumab mg to treat adults with polymyalgia rheumatica PMR who have not responded adequately to corticosteroids or cannot tolerate a reduction in their corticosteroid dose

Roche’s Gazyva/Gazyvaro becomes first FDA-approved treatment for primary membranous nephropathy

Roche has received approval from the US Food and Drug Administration FDA for GazyvaGazyvaro obinutuzumab to treat adults with primary membranous nephropathy pMN who are at risk of disease progression

Cyclarity Therapeutics Receives FDA Clearance for UDP-003 Clinical Trial Application in the US

Cyclarity Therapeutics Inc has received clearance from the US Food and Drug Administration FDA for its Investigational New Drug IND application for UDP enabling the company to expand its atherosclerosis clinical development programme into the United States

Santhera Signs Distribution Agreement with SteinCares for AGAMREE in 31 Latin American and Caribbean Countries

Cyclarity Therapeutics Inc has received clearance from the US Food and Drug Administration FDA for its Investigational New Drug IND application for UDP enabling the company to expand its atherosclerosis clinical development programme into the United States